Immune-mediated inflammatory disease patients’ preferences in adverse drug reaction information regarding biologics
Objectives: Patient-reported outcomes (PROs) are increasingly used in studies and medical practice to obtain information on patients’ perspectives toward their treatment or disease. However, most study outcomes are primarily directed at healthcare professionals. It was aimed to obtain insight in which type of information immune-mediated inflammatory disease (IMID) patients prefer to receive after participating in the Dutch Biologic Monitor (DBM), a PRO-based prospective cohort event monitoring system focused on adverse drug reactions (ADRs). Methods: A survey was conducted among DBM participants that wanted information about the results. Patients’ preferences were identified using twelve statements and rated with five-point Likert-type scales. Subgroup analyses and differences between statements were performed using Mann-Whitney U Tests. Results: The survey was completed by 591 patients (response rate 67.6%). Most respondents had inflammatory rheumatic diseases (76.8%) and used adalimumab (37.2%) or etanercept (33.2%). Respondents preferred results per IMID over aggregated results (p = <0.001). Information on whether patients with similar IMIDs experience ADRs (average 4.5), which biologics are most likely to cause ADRs (4.4) and whether ADRs disappear (4.4) were most interesting. Conclusion: DBM participants prefer to receive disease-specific information on ADRs that is tailored to their own biologic and IMID, including the outcome of ADRs.
|Keywords||Adverse drug reactions, biologics, communication, immune-mediated inflammatory diseases, patient preferences, study results|
|Persistent URL||dx.doi.org/10.1080/14740338.2020.1781090, hdl.handle.net/1765/128883|
|Journal||Expert Opinion on Drug Safety|
Kosse, L.J. (Leanne J.), Weits, G. (Gerda), Vonkeman, H.E, Spuls, P.I, van den Bemt, B.J.F, Tas, S.W, … Jessurun, N. (2020). Immune-mediated inflammatory disease patients’ preferences in adverse drug reaction information regarding biologics. Expert Opinion on Drug Safety, 1–5. doi:10.1080/14740338.2020.1781090